Abstract
BackgroundCognitive impairment is a key driver of disability in patients with early-stage Huntington’s disease (HD). SAGE-718 is an investigational NMDA receptor positive allosteric modulator that has been generally well tolerated...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
